Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

MicroPort CardioFlow Medtech Corporation
微创心通医疗科技有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2160)

VOLUNTARY ANNOUNCEMENT
CE MARK APPROVAL OF ALWIDE® PLUS BALLOON CATHETER

This announcement is made by MicroPort CardioFlow Medtech Corporation (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement and product registration progress of the Group.

The board of directors of the Company (the "**Board**") is pleased to announce that Alwide® Plus balloon catheter ("**Alwide® Plus**") received CE Mark (certification mark that indicates conformity with health, safety and environmental protection standards for products sold within the European Economic Area) approval.

Alwide® Plus is a surgical accessory product independently developed by the Company, designed to dilate calcified aortic valves prior to transcatheter aortic valve implantation ("**TAVI**"), and can reduce the challenges in performing valvuloplasty during TAVI procedures. Its key features include: (i) ultra low compliance ability enables more accurate balloon dilatation, avoiding blood vessel damage; (ii) high burst pressure performance enables effectively dilate severe calcification sites, better addressing the trait of high calcification in patients; and (iii) fast inflation/deflation performance minimizes the impact of prolonged blood flow obstruction on cardiac function, reducing pacing time and lowering surgical risk; and (iv) excellent puncture resistance ensures the safety of intraoperative balloon dilatation, providing physicians with a better user experience. Following approval by the National Medical Products Administration of the PRC (中國國家藥品監督管理局) in August 2021, Alwide® Plus has received registration approvals in more than 10 overseas countries or regions successively. The CE Mark approval of Alwide® Plus will provide a more optimized treatment solution for TAVI procedures in Europe, and will not only contribute to the Group's overseas revenue growth, but also facilitate the commercialization of the VitaFlow Liberty® transcatheter aortic valve and retrievable delivery system ("**VitaFlow Liberty®**") in Europe. It will also accelerate the registration process for both in other countries around the world, further enhancing the implementation of the Group's overseas strategy.

Alwide® Plus is the fourth independently developed product of the Group to obtain CE mark approval following VitaFlow Liberty®, AnchorMan® left atrial appendage closure system and its access system, which enriches the product portfolio of the Company in the important European market for structural heart disease. This once again demonstrates the Group's leading technological reserves and research and development capabilities in the global structural heart disease medical device field, as well as the foresight of its global strategic layout. Through the synergistic effects among the four products, they can mutually promote each other's commercialisation processes, further enhancing the Company's overall competitiveness in the international high-end medical device market.

By order of the Board
MicroPort CardioFlow Medtech Corporation
Chen Guoming
Chairman

Shanghai, PRC, August 18, 2025

As at the date of this announcement, the executive Directors are Mr. Zhang Ruinian, Mr. Zhao Liang and Ms. Yan Luying, the non-executive Directors are Mr. Chen Guoming, Mr. Zhang Junjie and Ms. Wu Xia, and the independent non-executive Directors are Mr. Jonathan H. Chou, Ms. Sun Zhixiang and Dr. Hu Bingshan.